Skip to Content

Non-Linear Correlation between Survival Improvements in Clinical Trials and Real-World Outcomes

Listen to Marco Donia, a clinical scientist from the National Center for Cancer Immune Therapy in Denmark, as he shares his insights on real-world data and metastatic melanoma with data from DAMMED (Danish Metastatic Melanoma Database). The MEDtalk explores the impact of eligibility criteria in clinical trials, disparities in survival rates between clinical trials and clinical practice and describes which drug has increased survival significantly for metastatic melanoma patients in the past 20 years.

Marco Donia

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top